Alx Accounts Payable vs Other Stockholder Equity Analysis

ALXO Stock

USD 1.44 0.07 4.64%

Alx Oncology financial indicator trend analysis is way more than just evaluating Alx Oncology Holdings prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Alx Oncology Holdings is a good investment. Please check the relationship between Alx Oncology Accounts Payable and its Other Stockholder Equity accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alx Oncology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

Accounts Payable vs Other Stockholder Equity

Accounts Payable vs Other Stockholder Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Alx Oncology Holdings Accounts Payable account and Other Stockholder Equity. At this time, the significance of the direction appears to have strong relationship.

The correlation between Alx Oncology's Accounts Payable and Other Stockholder Equity is 0.74. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Other Stockholder Equity in the same time period over historical financial statements of Alx Oncology Holdings, assuming nothing else is changed. The correlation between historical values of Alx Oncology's Accounts Payable and Other Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Alx Oncology Holdings are associated (or correlated) with its Other Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Stockholder Equity has no effect on the direction of Accounts Payable i.e., Alx Oncology's Accounts Payable and Other Stockholder Equity go up and down completely randomly.

Correlation Coefficient

0.74

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Accounts Payable

An accounting item on the balance sheet that represents Alx Oncology obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Alx Oncology Holdings are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Other Stockholder Equity

Most indicators from Alx Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Alx Oncology Holdings current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alx Oncology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

At this time, Alx Oncology's Issuance Of Capital Stock is very stable compared to the past year. As of the 12th of December 2024, Sales General And Administrative To Revenue is likely to grow to 11.84, while Tax Provision is likely to drop 0.00.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	83.6M	127.4M	170.3M	178.8M
Cost Of Revenue	736K	1.5M	836K	1.4M

Total Operating Expenses Cost Of Revenue

Alx Oncology fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Capital Stock	Net Working Capital
Total Assets		0.68	0.65	-0.38	0.33	0.99	0.53	-0.85	-0.65	0.51	0.87	0.55	1.0	0.45	0.95	0.86	0.48	0.94	0.89	0.94	0.68	1.0	0.53	1.0	-0.96	0.99
Other Current Liab	0.68		1.0	0.14	0.01	0.71	0.97	-0.22	-1.0	0.85	0.26	0.99	0.62	0.47	0.81	0.81	0.94	0.82	0.82	0.84	0.18	0.66	0.98	0.62	-0.85	0.58
Total Current Liabilities	0.65	1.0		0.13	0.03	0.68	0.98	-0.19	-1.0	0.88	0.23	0.99	0.59	0.42	0.79	0.81	0.96	0.8	0.8	0.82	0.13	0.63	0.98	0.59	-0.82	0.54
Total Stockholder Equity	-0.38	0.14	0.13		-0.38	-0.31	0.14	0.74	-0.19	-0.08	-0.72	0.25	-0.42	0.01	-0.27	-0.17	0.19	-0.27	-0.24	-0.24	-0.18	-0.39	0.17	-0.41	0.22	-0.42
Other Liab	0.33	0.01	0.03	-0.38		0.3	-0.06	-0.43	-0.01	0.12	0.42	-0.07	0.34	-0.11	0.26	0.3	-0.12	0.25	0.44	0.24	-0.16	0.33	-0.07	0.34	-0.22	0.35
Net Tangible Assets	0.99	0.71	0.68	-0.31	0.3		0.56	-0.81	-0.69	0.56	0.83	0.59	0.98	0.52	0.97	0.87	0.51	0.97	0.91	0.97	0.66	0.99	0.56	0.98	-0.97	0.97
Property Plant And Equipment Net	0.53	0.97	0.98	0.14	-0.06	0.56		-0.08	-0.97	0.89	0.12	0.99	0.47	0.43	0.7	0.71	0.97	0.71	0.72	0.74	0.0	0.51	1.0	0.47	-0.74	0.42
Net Debt	-0.85	-0.22	-0.19	0.74	-0.43	-0.81	-0.08		0.18	-0.17	-1.0	-0.07	-0.89	-0.27	-0.7	-0.59	-0.03	-0.7	-0.63	-0.68	-0.69	-0.86	-0.06	-0.88	0.69	-0.9
Retained Earnings	-0.65	-1.0	-1.0	-0.19	-0.01	-0.69	-0.97	0.18		-0.87	-0.22	-0.99	-0.59	-0.46	-0.8	-0.8	-0.95	-0.8	-0.8	-0.83	-0.16	-0.63	-0.98	-0.59	0.83	-0.54
Accounts Payable	0.51	0.85	0.88	-0.08	0.12	0.56	0.89	-0.17	-0.87		0.21	0.85	0.45	0.24	0.72	0.78	0.91	0.74	0.72	0.74	-0.06	0.5	0.88	0.44	-0.67	0.39
Cash	0.87	0.26	0.23	-0.72	0.42	0.83	0.12	-1.0	-0.22	0.21		0.11	0.9	0.28	0.73	0.62	0.07	0.72	0.65	0.71	0.69	0.88	0.1	0.9	-0.71	0.91
Non Current Assets Total	0.55	0.99	0.99	0.25	-0.07	0.59	0.99	-0.07	-0.99	0.85	0.11		0.49	0.44	0.72	0.73	0.96	0.72	0.73	0.75	0.07	0.53	0.99	0.49	-0.76	0.44
Cash And Short Term Investments	1.0	0.62	0.59	-0.42	0.34	0.98	0.47	-0.89	-0.59	0.45	0.9	0.49		0.41	0.92	0.84	0.42	0.91	0.85	0.91	0.7	1.0	0.46	1.0	-0.93	1.0
Net Receivables	0.45	0.47	0.42	0.01	-0.11	0.52	0.43	-0.27	-0.46	0.24	0.28	0.44	0.41		0.54	0.16	0.23	0.55	0.59	0.54	0.21	0.46	0.43	0.42	-0.56	0.4
Common Stock Total Equity	0.95	0.81	0.79	-0.27	0.26	0.97	0.7	-0.7	-0.8	0.72	0.73	0.72	0.92	0.54		0.9	0.65	1.0	0.96	1.0	0.52	0.94	0.7	0.92	-0.98	0.89
Common Stock Shares Outstanding	0.86	0.81	0.81	-0.17	0.3	0.87	0.71	-0.59	-0.8	0.78	0.62	0.73	0.84	0.16	0.9		0.75	0.9	0.83	0.91	0.47	0.85	0.71	0.84	-0.88	0.81
Non Current Liabilities Total	0.48	0.94	0.96	0.19	-0.12	0.51	0.97	-0.03	-0.95	0.91	0.07	0.96	0.42	0.23	0.65	0.75		0.66	0.62	0.69	0.04	0.46	0.97	0.42	-0.67	0.37
Capital Surpluse	0.94	0.82	0.8	-0.27	0.25	0.97	0.71	-0.7	-0.8	0.74	0.72	0.72	0.91	0.55	1.0	0.9	0.66		0.95	1.0	0.51	0.94	0.71	0.91	-0.97	0.88
Other Current Assets	0.89	0.82	0.8	-0.24	0.44	0.91	0.72	-0.63	-0.8	0.72	0.65	0.73	0.85	0.59	0.96	0.83	0.62	0.95		0.96	0.31	0.88	0.72	0.85	-0.94	0.82
Other Stockholder Equity	0.94	0.84	0.82	-0.24	0.24	0.97	0.74	-0.68	-0.83	0.74	0.71	0.75	0.91	0.54	1.0	0.91	0.69	1.0	0.96		0.51	0.94	0.73	0.91	-0.98	0.88
Total Liab	0.68	0.18	0.13	-0.18	-0.16	0.66	0.0	-0.69	-0.16	-0.06	0.69	0.07	0.7	0.21	0.52	0.47	0.04	0.51	0.31	0.51		0.68	0.01	0.71	-0.53	0.73
Net Invested Capital	1.0	0.66	0.63	-0.39	0.33	0.99	0.51	-0.86	-0.63	0.5	0.88	0.53	1.0	0.46	0.94	0.85	0.46	0.94	0.88	0.94	0.68		0.51	1.0	-0.95	0.99
Property Plant And Equipment Gross	0.53	0.98	0.98	0.17	-0.07	0.56	1.0	-0.06	-0.98	0.88	0.1	0.99	0.46	0.43	0.7	0.71	0.97	0.71	0.72	0.73	0.01	0.51		0.46	-0.74	0.41
Total Current Assets	1.0	0.62	0.59	-0.41	0.34	0.98	0.47	-0.88	-0.59	0.44	0.9	0.49	1.0	0.42	0.92	0.84	0.42	0.91	0.85	0.91	0.71	1.0	0.46		-0.93	1.0
Capital Stock	-0.96	-0.85	-0.82	0.22	-0.22	-0.97	-0.74	0.69	0.83	-0.67	-0.71	-0.76	-0.93	-0.56	-0.98	-0.88	-0.67	-0.97	-0.94	-0.98	-0.53	-0.95	-0.74	-0.93		-0.91
Net Working Capital	0.99	0.58	0.54	-0.42	0.35	0.97	0.42	-0.9	-0.54	0.39	0.91	0.44	1.0	0.4	0.89	0.81	0.37	0.88	0.82	0.88	0.73	0.99	0.41	1.0	-0.91

Click cells to compare fundamentals

Alx Oncology Account Relationship Matchups

Alx Oncology fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	10.7M	436.1M	380.2M	306.5M	242.6M	254.3M
Other Current Liab	1.2M	6.0M	10.8M	19.2M	25.8M	27.1M
Total Current Liabilities	5.0M	6.2M	15.3M	28.3M	36.0M	37.8M
Total Stockholder Equity	(276K)	(118.5M)	(202.0M)	(325.5M)	189.7M	199.2M
Other Liab	547K	5K	1.8M	53K	61.0K	57.9K
Net Tangible Assets	(70.6M)	429.8M	363.0M	263.5M	303.0M	205.5M
Property Plant And Equipment Net	860K	52K	3.5M	9.8M	10.8M	11.4M
Net Debt	(3.6M)	(434.2M)	(362.9M)	(272.5M)	(5.2M)	(5.5M)
Retained Earnings	(72.8M)	(118.5M)	(202.0M)	(325.5M)	(486.3M)	(462.0M)
Accounts Payable	3.7M	4K	3.8M	8.1M	8.6M	4.6M
Cash	9.0M	434.2M	363.7M	282.9M	22.4M	21.3M
Non Current Assets Total	867K	1.8M	13.2M	35.5M	53.9M	56.6M
Cash And Short Term Investments	9.0M	434.2M	363.7M	282.9M	182.7M	234.8M
Common Stock Shares Outstanding	36.5M	39.8M	40.3M	40.7M	43.0M	40.8M
Liabilities And Stockholders Equity	10.7M	436.1M	(184.9M)	(282.4M)	242.6M	254.7M
Non Current Liabilities Total	6.0M	5K	1.8M	14.7M	16.8M	17.7M
Capital Surpluse	2.1M	548.3M	565.0M	589.7M	678.2M	375.5M
Other Current Assets	256K	3.5M	6.7M	4.8M	5.9M	4.1M
Other Stockholder Equity	2.1M	548.3M	565.0M	589.7M	675.7M	437.0M
Total Liab	11.0M	436.1M	17.1M	43.0M	52.8M	74.9M
Net Invested Capital	(65.2M)	429.8M	363.0M	272.9M	199.4M	210.5M
Property Plant And Equipment Gross	860K	52K	3.5M	10.2M	12.1M	12.7M
Total Current Assets	9.8M	434.2M	367.0M	271.0M	188.7M	234.8M
Accumulated Other Comprehensive Income	(1.4M)	(554.6M)	0.0	(845K)	256K	268.8K
Net Working Capital	4.8M	429.8M	351.7M	242.6M	152.7M	218.2M
Property Plant Equipment	860K	52K	897K	3.9M	4.5M	4.7M

Pair Trading with Alx Oncology

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alx Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alx Oncology will appreciate offsetting losses from the drop in the long position's value.

Moving against Alx Stock

0.72	BMY	Bristol Myers Squibb	Pair Corr
0.68	GILD	Gilead Sciences	Pair Corr
0.43	FLGC	Flora Growth Corp	Pair Corr
0.38	ESPR	Esperion Therapeutics	Pair Corr

The ability to find closely correlated positions to Alx Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alx Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alx Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alx Oncology Holdings to buy it.

The correlation of Alx Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alx Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alx Oncology Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Alx Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Alx Oncology Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alx Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alx Oncology Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alx Oncology Holdings Stock:

How To Invest In Alx

Details

Is Alx Stock a good investment?

Details

What is Alx Oncology's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alx Oncology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alx Oncology. If investors know Alx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alx Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.97)

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.49)

Return On Equity

(0.99)

The market value of Alx Oncology Holdings is measured differently than its book value, which is the value of Alx that is recorded on the company's balance sheet. Investors also form their own opinion of Alx Oncology's value that differs from its market value or its book value, called intrinsic value, which is Alx Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alx Oncology's market value can be influenced by many factors that don't directly affect Alx Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Alx Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alx Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alx Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Alx Accounts Payable vs Other Stockholder Equity Analysis

Accounts Payable vs Other Stockholder Equity

Accounts Payable vs Other Stockholder Equity Correlation Analysis

Correlation Coefficient

Accounts Payable

Other Stockholder Equity

Alx Oncology fundamental ratios Correlations

Alx Oncology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Alx Oncology fundamental ratios Accounts

Pair Trading with Alx Oncology

Moving against Alx Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Other Current Liab
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Net Invested Capital	+ 1.0	Cash And Short Term Investments

Cash	- 1.0	Net Debt
Retained Earnings	- 1.0	Total Current Liabilities
Retained Earnings	- 1.0	Other Current Liab
Non Current Assets Total	- 0.99	Retained Earnings
Capital Stock	- 0.98	Other Stockholder Equity
Capital Stock	- 0.98	Common Stock Total Equity